Natural product therapy for tuberculosis: Cucurbitacin E, found abundantly in Watermelons, among others, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 27/October/2016, 7.37 am

Natural product anti-inflammatory therapy for upper respiratory tract inflammatory diseases: Berberine increases the expression of negative regulator of inflammation MyD88(s), inhibits pro-inflammatory mediators in lungs, and alleviates the common respiratory pathogen nontypeable Haemophilus influenzae (NTHi)-exacerbated asthma & chronic obstructive pulmonary disease via up-regulation of its target gene, 27/October/2015, 6.33 am
October 27, 2016
Natural product-based PD-1 pathway blockade for Human cancer therapy: Isorhapontigenin, isolated from Aiphanes Aculeata, Norway/Sitka/White Spruce, inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 27/october/2016, 8.18 am
October 27, 2016
Show all

A study from the Max Plank Institute for Infection Biology, Berlin, Germany shows that “CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis.” This study was published in the 10 February 2014 issue of the“Journal of Clinical Investigation” [One of the best research journals in clinical medicine with an impact factor of 12.575] by Prof. Stefan H.E. Kaufman MJ, Geraldine Nouailles, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for tuberculosis: Cucurbitacin E, found abundantly in Watermelonsamong others, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene


What they say: 

Prof. Stefan Kaufman’s research team has shown earlier that knockdown of CXCL5 in mice inhibits recruitment of polymorphonuclear leukocytes, decreases pulmonary inflammation and inhibits the progression of pulmonary tuberculosis.


Significance:

Given that: (1) nearly 2.5 billion people out of 7.4 billion total world population are infected with M. tuberculosis; (2) majority of population in Asian and African countries test positive in tuberculin tests; (3) molecular pathways involved and the mechanism of development of drug-resistant tuberculosis is far from understood; (3) treating drug-resistant tuberculosis is still a daunting task; (6) tuberculosis is the second-leading cause of death–first being the HIV–due to an infectious disease; (7) in 2010, out of the 88 lakhs patients test positive for TB, 14.5 lakhs patients died; (8) billions of dollars are being spent each year globally for the treatment of tuberculosis; and (9) most of the TB cases are registered in developing countries—that cannot afford high-cost required for the treatment of drug-resistant TB—compared to developed countries, there is an urgent need to find: (i) a way to inhibit drug-resistant tuberculosis; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free-Natural product-based drug that prevents relapse/recurrence of drug-resistant TB.


What we say: Research Findings: 

This study suggests a natural product-based therapy for life-threatening tuberculosis. Cucurbitacin E, by increasing the expression of its target gene, it may: (1) inhibit TLR-2 expression; (2) increase the expression of phosphatase MKP-1; (3) suppress the expression of Chemokine CXCL5 (C-X-C Motif Chemokine Ligand 5); (4) inhibit the recruitment of polymorphonuclear leukocytes; (5) decrease lung inflammation/injury; (6) promote clearance of M.tuberculosis; and (7) inhibit the progression of pulmonary tuberculosis. Together, pharmacological formulations encompassing “Cucurbitacin E or its analouges may be used to treat pulmonary tuberculosis.


Watermelons. Figure 1 Cucurbitacin E, found abundantly in Watermelons, inhibits pulmonary tuberculosis via down-regulation of (Toll-like receptor-TLR) TLR-2 and Chemokine CXCL5 and up-regulation of phosphatase MKP-1

Figure 1 Cucurbitacin E, found abundantly in Watermelons, inhibits pulmonary tuberculosis via down-regulation of (Toll-like receptor-TLR) TLR-2 and Chemokine CXCL5 and up-regulation of phosphatase MKP-1

Cucurbitacin E

Watermelon

Watermelons


Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, Natural product therapy for tuberculosis:  Cucurbitacin E, found abundantly in Watermelonsamong others,  increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 27/October/2016, 7.37 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Undisclosed information: How Cucurbitacin E: (1) increases the expression of MKP-1; (2) inhibits TLR-2 signaling; and (3) inhibits Chemokine CXCL5 expression

Amount: $300

satisfaction-guarantee

Results-guaranteed-if-not-refunded

Comments are closed.